Presented for research literature review only Heald AH et al
Motohashi H, Katsuoka F, Engel JD, Yamamoto M
The medication is patient-specific, compounded and prepared by a state-licensed pharmacy
In a statement to CBS News about this lawsuit and others against it, Novo Nordisk said in part, "The known risks and benefits of semaglutide and liraglutide medicines are described in their FDA-approved product labeling." The company wrote that "the allegations in the lawsuits are without merit" and said it intends to "vigorously defend against these claims." Novo Nordisk also said semaglutide, the drug sold under the Ozempic and Wegovy brand names, has been extensively examined in robust clinical development programs and large real world evidence studies
Patients should be alert to warning signs requiring urgent medical attention, including severe abdominal pain (especially if radiating to the back), persistent vomiting, or signs of gallbladder disease or pancreatitis
Sie knnen sich das Medikament 1-mal in der Woche selbststndig unter die Haut spritzen